{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:26:24Z","timestamp":1791462384021,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejpb.2020.11.019","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T11:18:39Z","timestamp":1606475919000},"page":"166-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation\u2014A proof-of-principle study in a P. aeruginosa lung infection model"],"prefix":"10.1016","volume":"158","author":[{"given":"Yu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Yoon Kyung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Y.T.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuncheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warwick J.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Kutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak-Kim","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2020.11.019_b0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2018.09.024","article-title":"Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa","volume":"551","author":"Lin","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.11.019_b0010","doi-asserted-by":"crossref","first-page":"e00019","DOI":"10.1128\/CMR.00019-18","article-title":"Epidemiology, biology, and impact of clonal pseudomonas aeruginosa infections in cystic fibrosis","volume":"31","author":"Parkins","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejpb.2020.11.019_b0015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01953-2017","article-title":"The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis","volume":"51","author":"Ara\u00fajo","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejpb.2020.11.019_b0020","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cmi.2019.06.011","article-title":"Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients","volume":"26","author":"Ekl\u00f6f","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejpb.2020.11.019_b0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1054\/drup.2000.0152","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment","volume":"3","author":"Hancock","year":"2000","journal-title":"Drug. Resist. Updates."},{"key":"10.1016\/j.ejpb.2020.11.019_b0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","article-title":"Phage therapy: a renewed approach to combat antibiotic-resistant bacteria","volume":"25","author":"Kortright","year":"2019","journal-title":"Cell Host Microbe."},{"key":"10.1016\/j.ejpb.2020.11.019_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molcel.2019.03.015","article-title":"Molecular basis of phage communication","volume":"74","author":"Rajaure","year":"2019","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejpb.2020.11.019_b0040","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.45.3.649-659.2001","article-title":"Bacteriophage therapy","volume":"45","author":"Sulakvelidze","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2020.11.019_b0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mib.2019.03.005","article-title":"Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy","volume":"51","author":"Segall","year":"2019","journal-title":"Curr. Opi. Microbiol."},{"key":"10.1016\/j.ejpb.2020.11.019_b0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.addr.2018.08.001","article-title":"Phage therapy for respiratory infections","volume":"133","author":"Chang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2020.11.019_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106628","article-title":"A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages","volume":"9","author":"Torres-Barcel\u00f3","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2020.11.019_b0060","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.3390\/v6103778","article-title":"Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms","volume":"6","author":"Coulter","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.ejpb.2020.11.019_b0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajme.2015.05.002","article-title":"Bacteriophage-antibiotic synergism to control planktonic and biofilm producing clinical isolates of Pseudomonas aeruginosa","volume":"52","author":"Nouraldin","year":"2016","journal-title":"Alexandria. Med. J."},{"key":"10.1016\/j.ejpb.2020.11.019_b0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.resmic.2012.08.008","article-title":"Phage-antibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa","volume":"164","author":"Knezevic","year":"2013","journal-title":"Res. Microbiol."},{"key":"10.1016\/j.ejpb.2020.11.019_b0075","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.resmic.2018.04.008","article-title":"Combined bacteriophages and antibiotics as an efficient therapy against VRE Enterococcus faecalis in a mouse model","volume":"169","author":"Gelman","year":"2018","journal-title":"Res. Microbiol."},{"key":"10.1016\/j.ejpb.2020.11.019_b0080","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1128\/AEM.02850-14","article-title":"Burkholderia cepacia complex phage-antibiotic synergy (PAS): antibiotics stimulate lytic phage activity","volume":"81","author":"Kamal","year":"2015","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.ejpb.2020.11.019_b0085","first-page":"703","article-title":"Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence","volume":"215","author":"Oechslin","year":"2016","journal-title":"J. Infect. Dis"},{"key":"10.1016\/j.ejpb.2020.11.019_b0090","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1099\/jmm.0.2008\/002873-0","article-title":"Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice","volume":"57","author":"Chhibber","year":"2008","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.ejpb.2020.11.019_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056022","article-title":"Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections","volume":"8","author":"Chhibber","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2020.11.019_b0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2106\/JBJS.K.01135","article-title":"Bacteriophage therapy in implant-related infections: an experimental study","volume":"95","author":"Yilmaz","year":"2013","journal-title":"JBJS"},{"key":"10.1016\/j.ejpb.2020.11.019_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157626","article-title":"In vivo assessment of phage and linezolid based implant coatings for treatment of methicillin resistant S. aureus (MRSA) mediated orthopaedic device related infections","volume":"11","author":"Kaur","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2020.11.019_b0110","first-page":"37","article-title":"Isolation and characterization of a lytic bacteriophage (vB_PmiS-TH) and its application in combination with ampicillin against planktonic and biofilm forms of proteus mirabilis isolated from urinary tract infection","volume":"28","author":"Yazdi","year":"2018","journal-title":"J. Mol. Microbiol."},{"key":"10.1016\/j.ejpb.2020.11.019_b0115","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/v11040343","article-title":"Current state of compassionate phage therapy","volume":"11","author":"McCallin","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ejpb.2020.11.019_b0120","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00253-019-09629-x","article-title":"Bacteriophage-host arm race: An update on the mechanism of phage resistance in bacteria and revenge of the phage with the perspective for phage therapy","volume":"103","author":"Azam","year":"2019","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.ejpb.2020.11.019_b0125","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.ejpb.2020.11.019_b0130","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1111\/ajt.15503","article-title":"Early clinical experience of bacteriophage therapy in 3 lung transplant recipients","volume":"19","author":"Aslam","year":"2019","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.ejpb.2020.11.019_b0135","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1164\/rccm.201904-0839LE","article-title":"Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by Pseudomonas aeruginosa","volume":"200","author":"Maddocks","year":"2019","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"10.1016\/j.ejpb.2020.11.019_b0140","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.healun.2019.01.012","article-title":"Safety and efficacy of bacteriophage therapy in lung transplant candidates and recipients","volume":"38","author":"Courtwright","year":"2019","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.ejpb.2020.11.019_b0145","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.resmic.2018.05.001","article-title":"Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report","volume":"169","author":"Hoyle","year":"2018","journal-title":"Res. Microbiol."},{"key":"10.1016\/j.ejpb.2020.11.019_b0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2014.10.022","article-title":"Inhaled formulations and pulmonary drug delivery systems for respiratory infections","volume":"85","author":"Zhou","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2020.11.019_b0155","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/17425247.2020.1712356","article-title":"Recent advances in aerosol devices for the delivery of inhaled medications","volume":"17","author":"Ari","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2020.11.019_b0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/jam.1991.4.151","article-title":"Dry powder inhalers: advantages and limitations","volume":"4","author":"Crompton","year":"1991","journal-title":"J. Aerosol. Med."},{"key":"10.1016\/j.ejpb.2020.11.019_b0165","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejpb.2019.08.004","article-title":"Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections","volume":"142","author":"Lin","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.11.019_b0170","doi-asserted-by":"crossref","first-page":"e01714","DOI":"10.1128\/AAC.01714-17","article-title":"Proof-of-principle study in a murine lung infection model of antipseudomonal activity of phage PEV20 in a dry-powder formulation","volume":"62","author":"Chang","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2020.11.019_b0175","doi-asserted-by":"crossref","first-page":"e0150606","DOI":"10.1371\/journal.pone.0150606","article-title":"A protocol for the comprehensive flow cytometric analysis of immune cells in normal and inflamed murine non-lymphoid tissues","volume":"11","author":"Yu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2020.11.019_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168615","article-title":"Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms","volume":"12","author":"Chaudhry","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2020.11.019_b0185","doi-asserted-by":"crossref","first-page":"26717","DOI":"10.1038\/srep26717","article-title":"Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa","volume":"6","author":"Chan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2020.11.019_b0190","doi-asserted-by":"crossref","first-page":"ftz011","DOI":"10.1093\/femspd\/ftz011","article-title":"P. aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage\u2013ciprofloxacin combination: \u2014monitoring the phage\u2013P. aeruginosa biofilms interactions","volume":"77","author":"Henriksen","year":"2019","journal-title":"Pathog. Dis."},{"key":"10.1016\/j.ejpb.2020.11.019_b0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000799","article-title":"Phage-antibiotic synergy (PAS): \u03b2-lactam and quinolone antibiotics stimulate virulent phage growth","volume":"2","author":"Comeau","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2020.11.019_b0200","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1128\/AEM.00526-16","article-title":"In vivo application of bacteriophage as a potential therapeutic agent to control OXA-66-like carbapenemase-producing Acinetobacter baumannii strains belonging to sequence type 357","volume":"82","author":"Jeon","year":"2016","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.ejpb.2020.11.019_b0205","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00003088-200342040-00002","article-title":"Pharmacokinetic principles of bacteriophage therapy","volume":"42","author":"Payne","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2020.11.019_b0210","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1128\/AAC.01426-15","article-title":"Antipseudomonal bacteriophage reduces infective burden and inflammatory response in murine lung","volume":"60","author":"Pabary","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2020.11.019_b0215","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1086\/649227","article-title":"Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection","volume":"201","author":"Carmody","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejpb.2020.11.019_b0220","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1086\/651135","article-title":"Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections","volume":"201","author":"Debarbieux","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejpb.2020.11.019_b0225","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1128\/AAC.02388-13","article-title":"Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections","volume":"58","author":"Semler","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2020.11.019_b0230","doi-asserted-by":"crossref","first-page":"e00029","DOI":"10.1128\/mBio.00029-12","article-title":"Bacteriophages \u03d5MR299-2 and \u03d5NH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells","volume":"3","author":"Alemayehu","year":"2012","journal-title":"MBio"},{"key":"10.1016\/j.ejpb.2020.11.019_b0235","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1128\/AAC.01596-13","article-title":"Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections","volume":"57","author":"Henry","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2020.11.019_b0240","doi-asserted-by":"crossref","first-page":"14802","DOI":"10.1038\/srep14802","article-title":"Mammalian Host-Versus-Phage immune response determines phage fate in vivo","volume":"5","author":"Hodyra-Stefaniak","year":"2015","journal-title":"Sci. Rep"},{"key":"10.1016\/j.ejpb.2020.11.019_b0245","first-page":"994","article-title":"Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models","volume":"49","author":"Tiwari","year":"2011","journal-title":"Res. J. Microbiol."},{"key":"10.1016\/j.ejpb.2020.11.019_b0250","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jtbi.2017.06.037","article-title":"Modeling the synergistic elimination of bacteria by phage and the innate immune system","volume":"429","author":"Leung","year":"2017","journal-title":"J. Theor. Biol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120303520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120303520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:42:09Z","timestamp":1760546529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641120303520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":50,"alternative-id":["S0939641120303520"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.11.019","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation\u2014A proof-of-principle study in a P. aeruginosa lung infection model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}